{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,10,6]],"date-time":"2026-10-06T03:00:39Z","timestamp":1791255639590,"version":"4.1.0"},"reference-count":72,"publisher":"Elsevier BV","issue":"2","license":[{"start":{"date-parts":[[2011,1,1]],"date-time":"2011-01-01T00:00:00Z","timestamp":1293840000000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"},{"start":{"date-parts":[[2011,1,1]],"date-time":"2011-01-01T00:00:00Z","timestamp":1293840000000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/legal\/tdmrep-license"},{"start":{"date-parts":[[2013,7,17]],"date-time":"2013-07-17T00:00:00Z","timestamp":1374019200000},"content-version":"vor","delay-in-days":928,"URL":"http:\/\/www.elsevier.com\/open-access\/userlicense\/1.0\/"},{"start":{"date-parts":[[2011,1,1]],"date-time":"2011-01-01T00:00:00Z","timestamp":1293840000000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-017"},{"start":{"date-parts":[[2011,1,1]],"date-time":"2011-01-01T00:00:00Z","timestamp":1293840000000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-037"},{"start":{"date-parts":[[2011,1,1]],"date-time":"2011-01-01T00:00:00Z","timestamp":1293840000000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-012"},{"start":{"date-parts":[[2011,1,1]],"date-time":"2011-01-01T00:00:00Z","timestamp":1293840000000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-029"},{"start":{"date-parts":[[2011,1,1]],"date-time":"2011-01-01T00:00:00Z","timestamp":1293840000000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-004"}],"content-domain":{"domain":["cell.com","elsevier.com","sciencedirect.com"],"crossmark-restriction":true},"short-container-title":["Neuron"],"published-print":{"date-parts":[[2011,1]]},"DOI":"10.1016\/j.neuron.2011.01.002","type":"journal-article","created":{"date-parts":[[2011,1,27]],"date-time":"2011-01-27T04:25:30Z","timestamp":1296102330000},"page":"203-213","update-policy":"https:\/\/doi.org\/10.1016\/elsevier_cm_policy","source":"Crossref","is-referenced-by-count":331,"title":["Anti-A\u03b2 Therapeutics in Alzheimer's Disease: The Need for a Paradigm Shift"],"prefix":"10.1016","volume":"69","author":[{"given":"Todd E.","family":"Golde","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Lon S.","family":"Schneider","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Edward H.","family":"Koo","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"78","reference":[{"key":"10.1016\/j.neuron.2011.01.002_bib1","doi-asserted-by":"crossref","first-page":"411","DOI":"10.1124\/jpet.108.140327","article-title":"Dynamics of Abeta turnover and deposition in different beta-amyloid precursor protein transgenic mouse models following gamma-secretase inhibition","volume":"327","author":"Abramowski","year":"2008","journal-title":"J. Pharmacol. Exp. Ther."},{"key":"10.1016\/j.neuron.2011.01.002_bib2","doi-asserted-by":"crossref","first-page":"158","DOI":"10.1016\/j.jalz.2010.01.009","article-title":"2010 Alzheimer's disease facts and figures","volume":"6","year":"2010","journal-title":"Alzheimers Dement."},{"key":"10.1016\/j.neuron.2011.01.002_bib3","unstructured":"Alzheimer's Disease International. (2010). World Alzheimer Report 2010.\u00a0http:\/\/www.alz.org\/documents\/national\/World_Alzheimer_Report_2010_Summary(1).pdf."},{"key":"10.1016\/j.neuron.2011.01.002_bib4","doi-asserted-by":"crossref","first-page":"301","DOI":"10.1101\/lm.43701","article-title":"Learning and memory in transgenic mice modeling Alzheimer's disease","volume":"8","author":"Ashe","year":"2001","journal-title":"Learn. Mem."},{"key":"10.1016\/j.neuron.2011.01.002_bib5","doi-asserted-by":"crossref","first-page":"631","DOI":"10.1016\/j.neuron.2010.04.031","article-title":"Probing the biology of Alzheimer's disease in mice","volume":"66","author":"Ashe","year":"2010","journal-title":"Neuron"},{"issue":"3, Suppl 2","key":"10.1016\/j.neuron.2011.01.002_bib6","doi-asserted-by":"crossref","first-page":"S63","DOI":"10.1097\/00002093-200607001-00009","article-title":"Postmortem indices linking risk factors to cognition: Results from the Religious Order Study and the Memory and Aging Project","volume":"20","author":"Bennett","year":"2006","journal-title":"Alzheimer Dis. Assoc. Disord."},{"key":"10.1016\/j.neuron.2011.01.002_bib7","doi-asserted-by":"crossref","first-page":"1837","DOI":"10.1212\/01.wnl.0000219668.47116.e6","article-title":"Neuropathology of older persons without cognitive impairment from two community-based studies","volume":"66","author":"Bennett","year":"2006","journal-title":"Neurology"},{"key":"10.1016\/j.neuron.2011.01.002_bib8","doi-asserted-by":"crossref","first-page":"213","DOI":"10.1602\/neurorx.1.2.213","article-title":"Cerebrospinal fluid protein biomarkers for Alzheimer's disease","volume":"1","author":"Blennow","year":"2004","journal-title":"NeuroRx"},{"key":"10.1016\/j.neuron.2011.01.002_bib9","doi-asserted-by":"crossref","first-page":"351","DOI":"10.1016\/S0197-4580(97)00056-0","article-title":"Frequency of stages of Alzheimer-related lesions in different age categories","volume":"18","author":"Braak","year":"1997","journal-title":"Neurobiol. Aging"},{"key":"10.1016\/j.neuron.2011.01.002_bib10","doi-asserted-by":"crossref","first-page":"34","DOI":"10.1126\/science.3513311","article-title":"A receptor-mediated pathway for cholesterol homeostasis","volume":"232","author":"Brown","year":"1986","journal-title":"Science"},{"key":"10.1016\/j.neuron.2011.01.002_bib11","doi-asserted-by":"crossref","first-page":"125","DOI":"10.1016\/S1047-2797(99)00042-3","article-title":"Design of Physicians' Health Study II\u2014a randomized trial of beta-carotene, vitamins E and C, and multivitamins, in prevention of cancer, cardiovascular disease, and eye\u00a0disease, and review of results of completed trials","volume":"10","author":"Christen","year":"2000","journal-title":"Ann. Epidemiol."},{"key":"10.1016\/j.neuron.2011.01.002_bib12","doi-asserted-by":"crossref","first-page":"190","DOI":"10.1016\/S1474-4422(05)70022-3","article-title":"The Women's Health Initiative Memory Study: Findings and implications for treatment","volume":"4","author":"Craig","year":"2005","journal-title":"Lancet Neurol."},{"issue":"1, Suppl 1","key":"10.1016\/j.neuron.2011.01.002_bib13","first-page":"S2","article-title":"Alzheimer's disease: Etiologies, pathophysiology, cognitive reserve, and treatment opportunities","volume":"51","author":"Cummings","year":"1998","journal-title":"Neurology"},{"key":"10.1016\/j.neuron.2011.01.002_bib14","doi-asserted-by":"crossref","first-page":"721","DOI":"10.1016\/S0197-4580(01)00245-7","article-title":"Reduced effectiveness of Abeta1-42 immunization in APP transgenic mice with significant amyloid deposition","volume":"22","author":"Das","year":"2001","journal-title":"Neurobiol. Aging"},{"key":"10.1016\/j.neuron.2011.01.002_bib15","doi-asserted-by":"crossref","first-page":"949","DOI":"10.1001\/archneurol.2010.179","article-title":"Diagnosis-independent Alzheimer disease biomarker signature in cognitively normal elderly people","volume":"67","author":"De Meyer","year":"2010","journal-title":"Arch. Neurol."},{"key":"10.1016\/j.neuron.2011.01.002_bib16","doi-asserted-by":"crossref","first-page":"2253","DOI":"10.1001\/jama.2008.683","article-title":"Ginkgo biloba for prevention of dementia: A randomized controlled trial","volume":"300","author":"DeKosky","year":"2008","journal-title":"JAMA"},{"key":"10.1016\/j.neuron.2011.01.002_bib17","doi-asserted-by":"crossref","first-page":"209","DOI":"10.1016\/S0749-0690(05)70066-5","article-title":"Neuropathology of Alzheimer's disease and other dementias","volume":"17","author":"Dickson","year":"2001","journal-title":"Clin. Geriatr. Med."},{"key":"10.1016\/j.neuron.2011.01.002_bib18","doi-asserted-by":"crossref","first-page":"207","DOI":"10.1016\/S0140-6736(08)61074-0","article-title":"Effect of dimebon on cognition, activities of daily living, behaviour, and global function in patients with mild-to-moderate Alzheimer's disease: A randomised, double-blind, placebo-controlled study","volume":"372","author":"Doody","year":"2008","journal-title":"Lancet"},{"key":"10.1016\/j.neuron.2011.01.002_bib19","doi-asserted-by":"crossref","first-page":"246","DOI":"10.1016\/S1474-4422(04)00710-0","article-title":"Amnestic MCI or prodromal Alzheimer's disease?","volume":"3","author":"Dubois","year":"2004","journal-title":"Lancet Neurol."},{"key":"10.1016\/j.neuron.2011.01.002_bib20","doi-asserted-by":"crossref","first-page":"1118","DOI":"10.1016\/S1474-4422(10)70223-4","article-title":"Revising the definition of Alzheimer's disease: A new lexicon","volume":"9","author":"Dubois","year":"2010","journal-title":"Lancet Neurol."},{"key":"10.1016\/j.neuron.2011.01.002_bib21","doi-asserted-by":"crossref","first-page":"1349","DOI":"10.1001\/jama.1997.03550160069041","article-title":"Effects of age, sex, and ethnicity on the association between apolipoprotein E genotype and Alzheimer disease. A meta-analysis","volume":"278","author":"Farrer","year":"1997","journal-title":"JAMA"},{"key":"10.1016\/j.neuron.2011.01.002_bib22","doi-asserted-by":"crossref","first-page":"1055","DOI":"10.1038\/nm1113","article-title":"Neurodegenerative diseases: A decade of discoveries paves the way for therapeutic breakthroughs","volume":"10","author":"Forman","year":"2004","journal-title":"Nat. Med."},{"key":"10.1016\/j.neuron.2011.01.002_bib23","doi-asserted-by":"crossref","first-page":"71","DOI":"10.1111\/j.1750-3639.2006.tb00563.x","article-title":"Genetic alterations of the BRI2 gene: Familial British and Danish dementias","volume":"16","author":"Ghiso","year":"2006","journal-title":"Brain Pathol."},{"key":"10.1016\/j.neuron.2011.01.002_bib24","doi-asserted-by":"crossref","first-page":"1495","DOI":"10.1212\/01.WNL.0000063311.58879.01","article-title":"Tangle and neuron numbers, but not amyloid load, predict cognitive status in Alzheimer's disease","volume":"60","author":"Giannakopoulos","year":"2003","journal-title":"Neurology"},{"key":"10.1016\/j.neuron.2011.01.002_bib25","doi-asserted-by":"crossref","first-page":"84","DOI":"10.1111\/j.1750-3639.2005.tb00104.x","article-title":"The Abeta hypothesis: Leading us to rationally-designed therapeutic strategies for the treatment or prevention of Alzheimer disease","volume":"15","author":"Golde","year":"2005","journal-title":"Brain Pathol."},{"key":"10.1016\/j.neuron.2011.01.002_bib26","doi-asserted-by":"crossref","first-page":"252","DOI":"10.1016\/j.expneurol.2009.07.035","article-title":"Targeting Abeta and tau in Alzheimer's disease, an early interim report","volume":"223","author":"Golde","year":"2010","journal-title":"Exp. Neurol."},{"key":"10.1016\/j.neuron.2011.01.002_bib27","doi-asserted-by":"crossref","first-page":"1491","DOI":"10.1126\/science.1062097","article-title":"Formation of neurofibrillary tangles in P301l tau transgenic mice induced by Abeta 42 fibrils","volume":"293","author":"G\u00f6tz","year":"2001","journal-title":"Science"},{"key":"10.1016\/j.neuron.2011.01.002_bib28","doi-asserted-by":"crossref","first-page":"543","DOI":"10.1016\/S0002-9343(02)01270-6","article-title":"Effect of postmenopausal hormone therapy on cognitive function: The Heart and Estrogen\/progestin Replacement Study","volume":"113","author":"Grady","year":"2002","journal-title":"Am. J. Med."},{"key":"10.1016\/j.neuron.2011.01.002_bib29","doi-asserted-by":"crossref","first-page":"23","DOI":"10.1016\/S0140-6736(02)09328-5","article-title":"MRC\/BHF Heart Protection Study of antioxidant vitamin supplementation in 20,536 high-risk individuals: A randomised placebo-controlled trial","volume":"360","year":"2002","journal-title":"Lancet"},{"key":"10.1016\/j.neuron.2011.01.002_bib30","doi-asserted-by":"crossref","first-page":"7","DOI":"10.1016\/S0140-6736(02)09327-3","article-title":"MRC\/BHF Heart Protection Study of cholesterol lowering with simvastatin in 20,536 high-risk individuals: A randomised placebo-controlled trial","volume":"360","year":"2002","journal-title":"Lancet"},{"key":"10.1016\/j.neuron.2011.01.002_bib31","doi-asserted-by":"crossref","first-page":"184","DOI":"10.1126\/science.1566067","article-title":"Alzheimer's disease: The amyloid cascade hypothesis","volume":"256","author":"Hardy","year":"1992","journal-title":"Science"},{"key":"10.1016\/j.neuron.2011.01.002_bib32","doi-asserted-by":"crossref","first-page":"353","DOI":"10.1126\/science.1072994","article-title":"The amyloid hypothesis of Alzheimer's disease: Progress and problems on the road to therapeutics","volume":"297","author":"Hardy","year":"2002","journal-title":"Science"},{"key":"10.1016\/j.neuron.2011.01.002_bib33","doi-asserted-by":"crossref","first-page":"2892","DOI":"10.1073\/pnas.050004797","article-title":"Apolipoprotein E isoform-dependent amyloid deposition and neuritic degeneration in a mouse model of Alzheimer's disease","volume":"97","author":"Holtzman","year":"2000","journal-title":"Proc. Natl. Acad. Sci. USA"},{"key":"10.1016\/j.neuron.2011.01.002_bib34","doi-asserted-by":"crossref","first-page":"1800","DOI":"10.1212\/01.wnl.0000260269.93245.d2","article-title":"Naproxen and celecoxib do not prevent AD in early results from a randomized controlled trial","volume":"68","author":"Lyketsos","year":"2007","journal-title":"Neurology"},{"key":"10.1016\/j.neuron.2011.01.002_bib35","doi-asserted-by":"crossref","first-page":"1355","DOI":"10.1093\/brain\/awp062","article-title":"Serial PIB and MRI in normal, mild cognitive impairment and Alzheimer's disease: Implications for\u00a0sequence of pathological events in Alzheimer's disease","volume":"132","author":"Jack","year":"2009","journal-title":"Brain"},{"key":"10.1016\/j.neuron.2011.01.002_bib36","doi-asserted-by":"crossref","first-page":"25","DOI":"10.1186\/alzrt49","article-title":"Dimebon disappointment","volume":"2","author":"Jones","year":"2010","journal-title":"Alzheimers Res Ther"},{"key":"10.1016\/j.neuron.2011.01.002_bib37","doi-asserted-by":"crossref","first-page":"189","DOI":"10.1602\/neurorx.1.2.189","article-title":"Biomarkers and surrogate markers: An FDA perspective","volume":"1","author":"Katz","year":"2004","journal-title":"NeuroRx"},{"key":"10.1016\/j.neuron.2011.01.002_bib38","doi-asserted-by":"crossref","first-page":"285","DOI":"10.1002\/sim.1716","article-title":"Designing a large prevention trial: Statistical issues","volume":"23","author":"Kryscio","year":"2004","journal-title":"Stat. Med."},{"key":"10.1016\/j.neuron.2011.01.002_bib39","doi-asserted-by":"crossref","first-page":"1487","DOI":"10.1126\/science.1058189","article-title":"Enhanced neurofibrillary degeneration in transgenic mice expressing mutant tau and APP","volume":"293","author":"Lewis","year":"2001","journal-title":"Science"},{"key":"10.1016\/j.neuron.2011.01.002_bib40","doi-asserted-by":"crossref","first-page":"93","DOI":"10.1016\/S0197-2456(01)00189-1","article-title":"Double placebo design in a prevention trial for Alzheimer's disease","volume":"23","author":"Martin","year":"2002","journal-title":"Control. Clin. Trials"},{"key":"10.1016\/j.neuron.2011.01.002_bib41","doi-asserted-by":"crossref","first-page":"93","DOI":"10.1016\/j.jalz.2008.09.004","article-title":"Alzheimer's Disease Anti-inflammatory Prevention Trial: Design, methods, and baseline results","volume":"5","author":"Meinert","year":"2009","journal-title":"Alzheimers Dement."},{"key":"10.1016\/j.neuron.2011.01.002_bib42","doi-asserted-by":"crossref","first-page":"101","DOI":"10.1385\/JMN:17:2:101","article-title":"Pathologic correlates of nondemented aging, mild cognitive impairment, and early-stage Alzheimer's disease","volume":"17","author":"Morris","year":"2001","journal-title":"J.\u00a0Mol. Neurosci."},{"key":"10.1016\/j.neuron.2011.01.002_bib43","doi-asserted-by":"crossref","first-page":"1571","DOI":"10.1001\/jama.283.12.1571","article-title":"Correlation between elevated levels of amyloid beta-peptide in the brain and cognitive decline","volume":"283","author":"N\u00e4slund","year":"2000","journal-title":"JAMA"},{"key":"10.1016\/j.neuron.2011.01.002_bib44","doi-asserted-by":"crossref","first-page":"467","DOI":"10.1002\/ana.20741","article-title":"1,026 experimental treatments in acute stroke","volume":"59","author":"O'Collins","year":"2006","journal-title":"Ann. Neurol."},{"key":"10.1016\/j.neuron.2011.01.002_bib45","doi-asserted-by":"crossref","first-page":"203","DOI":"10.1038\/nrd3078","article-title":"How to improve R&D productivity: The pharmaceutical industry's grand challenge","volume":"9","author":"Paul","year":"2010","journal-title":"Nat. Rev. Drug Discov."},{"key":"10.1016\/j.neuron.2011.01.002_bib46","doi-asserted-by":"crossref","first-page":"916","DOI":"10.1038\/nature08538","article-title":"Multimodal techniques for diagnosis and prognosis of Alzheimer's disease","volume":"461","author":"Perrin","year":"2009","journal-title":"Nature"},{"key":"10.1016\/j.neuron.2011.01.002_bib47","doi-asserted-by":"crossref","first-page":"479","DOI":"10.1146\/annurev.neuro.21.1.479","article-title":"Mutant genes in familial Alzheimer's disease and transgenic models","volume":"21","author":"Price","year":"1998","journal-title":"Annu. Rev. Neurosci."},{"key":"10.1016\/j.neuron.2011.01.002_bib48","doi-asserted-by":"crossref","first-page":"13363","DOI":"10.1073\/pnas.95.23.13363","article-title":"Prions","volume":"95","author":"Prusiner","year":"1998","journal-title":"Proc. Natl. Acad. Sci. USA"},{"key":"10.1016\/j.neuron.2011.01.002_bib49","doi-asserted-by":"crossref","first-page":"e338","DOI":"10.1371\/journal.pmed.0040338","article-title":"Cholinesterase inhibitors in mild cognitive impairment: A systematic review of randomised trials","volume":"4","author":"Raschetti","year":"2007","journal-title":"PLoS Med."},{"key":"10.1016\/j.neuron.2011.01.002_bib50","doi-asserted-by":"crossref","first-page":"3","DOI":"10.2217\/bmm.09.91","article-title":"Alzheimer's prevention initiative: A proposal to evaluate presymptomatic treatments as quickly as possible","volume":"4","author":"Reiman","year":"2010","journal-title":"Biomark Med"},{"key":"10.1016\/j.neuron.2011.01.002_bib51","doi-asserted-by":"crossref","first-page":"517","DOI":"10.1212\/WNL.53.3.517","article-title":"APOE genotype, plasma lipids, lipoproteins, and AD in community elderly","volume":"53","author":"Romas","year":"1999","journal-title":"Neurology"},{"key":"10.1016\/j.neuron.2011.01.002_bib52","doi-asserted-by":"crossref","first-page":"1226","DOI":"10.1001\/archneur.1997.00550220036011","article-title":"Genetic testing for Alzheimer disease. Practical and ethical issues","volume":"54","author":"Roses","year":"1997","journal-title":"Arch. Neurol."},{"issue":"Suppl","key":"10.1016\/j.neuron.2011.01.002_bib53","doi-asserted-by":"crossref","first-page":"S10","DOI":"10.1038\/nm1066","article-title":"Protein aggregation and neurodegenerative disease","volume":"10","author":"Ross","year":"2004","journal-title":"Nat. Med."},{"key":"10.1016\/j.neuron.2011.01.002_bib54","doi-asserted-by":"crossref","first-page":"65","DOI":"10.1016\/j.jalz.2007.10.001","article-title":"Disease-modifying therapies in Alzheimer's disease","volume":"4","author":"Salloway","year":"2008","journal-title":"Alzheimers Dement."},{"key":"10.1016\/j.neuron.2011.01.002_bib55","doi-asserted-by":"crossref","first-page":"388","DOI":"10.1016\/j.jalz.2009.07.038","article-title":"Current Alzheimer's disease clinical trials: Methods and placebo outcomes","volume":"5","author":"Schneider","year":"2009","journal-title":"Alzheimers Dement."},{"key":"10.1016\/j.neuron.2011.01.002_bib56","doi-asserted-by":"crossref","first-page":"200","DOI":"10.1002\/ana.21706","article-title":"The neuropathology of probable Alzheimer disease and mild cognitive impairment","volume":"66","author":"Schneider","year":"2009","journal-title":"Ann. Neurol."},{"key":"10.1016\/j.neuron.2011.01.002_bib57","doi-asserted-by":"crossref","DOI":"10.1001\/archneurol.2010.343","article-title":"Cholinesterase inhibitors and memantine use by patients in the Alzheimer Disease Neuroimaging Initiative","author":"Schneider","year":"2011","journal-title":"Arch. Neurol."},{"key":"10.1016\/j.neuron.2011.01.002_bib58","doi-asserted-by":"crossref","first-page":"741","DOI":"10.1152\/physrev.2001.81.2.741","article-title":"Alzheimer's disease: Genes, proteins, and therapy","volume":"81","author":"Selkoe","year":"2001","journal-title":"Physiol. Rev."},{"key":"10.1016\/j.neuron.2011.01.002_bib59","doi-asserted-by":"crossref","first-page":"403","DOI":"10.1002\/ana.21610","article-title":"Cerebrospinal fluid biomarker signature in Alzheimer's disease neuroimaging initiative subjects","volume":"65","author":"Shaw","year":"2009","journal-title":"Ann. Neurol."},{"key":"10.1016\/j.neuron.2011.01.002_bib60","doi-asserted-by":"crossref","first-page":"37","DOI":"10.1007\/s00401-009-0521-4","article-title":"Variations in the neuropathology of familial Alzheimer's disease","volume":"118","author":"Shepherd","year":"2009","journal-title":"Acta Neuropathol."},{"key":"10.1016\/j.neuron.2011.01.002_bib61","doi-asserted-by":"crossref","first-page":"534","DOI":"10.1016\/j.neuron.2008.11.007","article-title":"Linking Abeta and tau in late-onset Alzheimer's disease: A dual pathway hypothesis","volume":"60","author":"Small","year":"2008","journal-title":"Neuron"},{"key":"10.1016\/j.neuron.2011.01.002_bib62","doi-asserted-by":"crossref","first-page":"2663","DOI":"10.1001\/jama.2009.1913","article-title":"Ginkgo biloba for preventing cognitive decline in older adults: A randomized trial","volume":"302","author":"Snitz","year":"2009","journal-title":"JAMA"},{"key":"10.1016\/j.neuron.2011.01.002_bib63","doi-asserted-by":"crossref","first-page":"1942","DOI":"10.1212\/WNL.53.9.1942","article-title":"Rate of memory decline in AD is related to education and occupation: Cognitive reserve?","volume":"53","author":"Stern","year":"1999","journal-title":"Neurology"},{"key":"10.1016\/j.neuron.2011.01.002_bib64","doi-asserted-by":"crossref","first-page":"1476","DOI":"10.1001\/archneurol.2009.272","article-title":"Cognitive decline and brain volume loss as signatures of cerebral amyloid-beta peptide deposition identified with Pittsburgh compound B: Cognitive decline associated with Abeta deposition","volume":"66","author":"Storandt","year":"2009","journal-title":"Arch. Neurol."},{"key":"10.1016\/j.neuron.2011.01.002_bib65","doi-asserted-by":"crossref","first-page":"4725","DOI":"10.1073\/pnas.92.11.4725","article-title":"Apolipoprotein E and Alzheimer disease","volume":"92","author":"Strittmatter","year":"1995","journal-title":"Proc. Natl. Acad. Sci. USA"},{"issue":"9, Suppl 3","key":"10.1016\/j.neuron.2011.01.002_bib66","first-page":"S6","article-title":"The GuidAge study: Methodological issues. A 5-year double-blind randomized trial of the efficacy of EGb 761 for prevention of Alzheimer disease in patients over 70 with a memory complaint","volume":"67","author":"Vellas","year":"2006","journal-title":"Neurology"},{"issue":"9, Suppl 3","key":"10.1016\/j.neuron.2011.01.002_bib67","first-page":"S6","article-title":"The GuidAge study: Methodological issues. A 5-year double-blind randomized trial of the efficacy of EGb 761 for prevention of Alzheimer disease in patients over 70 with a memory complaint","volume":"67","author":"Vellas","year":"2006","journal-title":"Neurology"},{"key":"10.1016\/j.neuron.2011.01.002_bib68","doi-asserted-by":"crossref","first-page":"181","DOI":"10.1016\/j.neuron.2004.09.010","article-title":"Deciphering the molecular basis of memory failure in Alzheimer's disease","volume":"44","author":"Walsh","year":"2004","journal-title":"Neuron"},{"key":"10.1016\/j.neuron.2011.01.002_bib69","doi-asserted-by":"crossref","first-page":"31831","DOI":"10.1074\/jbc.M303592200","article-title":"Evidence that nonsteroidal anti-inflammatory drugs decrease amyloid beta 42 production by direct modulation of gamma-secretase activity","volume":"278","author":"Weggen","year":"2003","journal-title":"J. Biol. Chem."},{"key":"10.1016\/j.neuron.2011.01.002_bib70","doi-asserted-by":"crossref","unstructured":"Weiner, M.W., Aisen, P.S., Jack, C.R., Jr., Jagust, W.J., Trojanowski, J.Q., Shaw, L., Saykin, A.J., Morris, J.C., Cairns, N., Beckett, L.A., et\u00a0al. (2010). The Alzheimer's disease neuroimaging initiative: Progress report and future plans. Alzheimers Dement 6, 202-211 e207.","DOI":"10.1016\/j.jalz.2010.03.007"},{"key":"10.1016\/j.neuron.2011.01.002_bib71","doi-asserted-by":"crossref","first-page":"98","DOI":"10.1016\/j.jalz.2010.01.010","article-title":"The worldwide societal costs of dementia: Estimates for 2009","volume":"6","author":"Wimo","year":"2010","journal-title":"Alzheimers Dement."},{"key":"10.1016\/j.neuron.2011.01.002_bib72","doi-asserted-by":"crossref","first-page":"289","DOI":"10.1016\/S0928-4257(98)80035-1","article-title":"The role of A beta 42 in Alzheimer's disease","volume":"92","author":"Younkin","year":"1998","journal-title":"J. Physiol. Paris"}],"container-title":["Neuron"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0896627311000031?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0896627311000031?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2025,10,12]],"date-time":"2025-10-12T06:57:32Z","timestamp":1760252252000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S0896627311000031"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2011,1]]},"references-count":72,"journal-issue":{"issue":"2","published-print":{"date-parts":[[2011,1]]}},"alternative-id":["S0896627311000031"],"URL":"https:\/\/doi.org\/10.1016\/j.neuron.2011.01.002","relation":{"has-review":[{"id-type":"doi","id":"10.3410\/f.8654956.9169056","asserted-by":"object"}]},"ISSN":["0896-6273"],"issn-type":[{"value":"0896-6273","type":"print"}],"subject":[],"published":{"date-parts":[[2011,1]]},"assertion":[{"value":"Elsevier","name":"publisher","label":"This article is maintained by"},{"value":"Anti-A\u03b2 Therapeutics in Alzheimer's Disease: The Need for a Paradigm Shift","name":"articletitle","label":"Article Title"},{"value":"Neuron","name":"journaltitle","label":"Journal Title"},{"value":"https:\/\/doi.org\/10.1016\/j.neuron.2011.01.002","name":"articlelink","label":"CrossRef DOI link to publisher maintained version"},{"value":"article","name":"content_type","label":"Content Type"},{"value":"Copyright \u00a9 2011 Elsevier Inc. All rights reserved.","name":"copyright","label":"Copyright"}]}}